F2 Bioscience I 2017 Ltd

SEC source: 0001104659-22-073980 · tm2219298-1_4seq1.xml · nonDerivative · entry 3

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 537,392

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.72 to $13.35, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.direct: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways Holdings Limited ("Globeways") is the appointed manager of F2 Bioscience 2017. Dr. Morana Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001104659-22-073980 · tm2219298-1_4seq1.xml · nonDerivative · entry 2

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 567,023

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.35 to $12.92, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.direct: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways Holdings Limited ("Globeways") is the appointed manager of F2 Bioscience 2017. Dr. Morana Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001104659-22-073980 · tm2219298-1_4seq1.xml · nonDerivative · entry 1

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 616,976

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.58 to $12.99, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.direct: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways Holdings Limited ("Globeways") is the appointed manager of F2 Bioscience 2017. Dr. Morana Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 21

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 214,798 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F8 · ownership.nature: These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 20

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 71,599 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F7 · ownership.nature: These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. . The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 19

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 143,198 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F6 · ownership.nature: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 18

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 71,599 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F5 · ownership.nature: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 17

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 182,135 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F6 · ownership.nature: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 16

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 455,338 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F5 · ownership.nature: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 15

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 639,295 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F4 · ownership.nature: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 14

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 2,912,345 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F3 · ownership.nature: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. The Reporting Person is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 13

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,136,525 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F2 · ownership.nature: These securities are owned directly by Globeways Holdings Limited ("Globeways"). The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 12

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 104,762

F9 · ownership.nature: These securities are owned directly by F2 GC LLC ("F2 GC"). Globeways II is the appointed manager of F2 GC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 11

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 622,175

F5 · ownership.nature: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 10

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 214,798

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F8 · ownership.nature: These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 9

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 71,599

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F7 · ownership.nature: These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. . The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 8

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 325,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F6 · ownership.nature: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 7

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 526,937

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F5 · ownership.nature: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 6

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 182,135

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F6 · ownership.nature: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 5

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 455,338

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F5 · ownership.nature: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 4

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 639,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F4 · ownership.nature: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 3

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,912,345

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F3 · ownership.nature: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. The Reporting Person is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 2

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,136,525

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F2 · ownership.nature: These securities are owned directly by Globeways Holdings Limited ("Globeways"). The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.